PCM
TTNP

Perkins Capital Management’s Titan Pharmaceuticals TTNP Stock Holding History

Perkins Capital Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-151
Closed -$162K – 121
2019
Q1 		$162K Hold
151
– – 0.11% 115
2018
Q4 		$122K Sell
151
-182
-55% -$204K 0.09% 111
2018
Q3 		$249K Buy
+333
New +$905K 0.15% 113

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $75.9M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Perkins Capital Management's TTNP Position: Q2 2019 in Review

Perkins Capital Management sold out of Titan Pharmaceuticals (TTNP) in Q2 2019, closing a stake of 151 shares — an estimated $162K sold.

Perkins Capital Management first reported a position in TTNP in Q3 2018 and held it in 3 quarters. The position peaked at $249K in Q3 2018. 15 funds tracked by Wall St. Rank hold TTNP as of Q2 2019.

  • Perkins Capital Management reported no remaining Titan Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Perkins Capital Management sold 151 Titan Pharmaceuticals shares in Q2 2019, an estimated $162K.
  • Perkins Capital Management first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Perkins Capital Management's Titan Pharmaceuticals position peaked at $249K in Q3 2018.
  • 15 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2019.

Based on Perkins Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.